Rheumatoid Arthritis Trial, Recruiting (NCT07126431)

Rheumatoid Arthritis Trial, Recruiting NCT07126431 Sponsor: Peking University Third Hospital Condition: Rheumatoid Arthritis

Printed from Voxsanity (voxsanity.com.au) — NCT07126431 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Rheumatoid Arthritis

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

You have been diagnosed with rheumatoid arthritis (RA) according to recognised medical guidelines (either from 1987 or 2010 standards)
You are older than 18 years of age
You have been taking standard disease-modifying medications (DMARDs) for at least 1 year
Your rheumatoid arthritis has been classed as "difficult-to-treat" or "refractory," meaning it has not responded well enough to treatments tried so far (confirm with trial site)
You are willing and able to give written consent to take part in the study

Who may not be able to join:

You are under 18 years of age
You have been taking disease-modifying medications (DMARDs) for less than 1 year
You are not willing to take part in this type of observational study (called a cohort study)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 7 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: 13810098187

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT07126431

Sponsor: Peking University Third Hospital

Phase: Not Applicable

Status: Recruiting

Condition: Rheumatoid Arthritis

Trial contact: 13810098187

More information: https://clinicaltrials.gov/study/NCT07126431

Eligibility summary (AI generated)

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

You have been diagnosed with rheumatoid arthritis (RA) according to recognised medical guidelines (either from 1987 or 2010 standards)
You are older than 18 years of age
You have been taking standard disease-modifying medications (DMARDs) for at least 1 year
Your rheumatoid arthritis has been classed as "difficult-to-treat" or "refractory," meaning it has not responded well enough to treatments tried so far (confirm with trial site)
You are willing and able to give written consent to take part in the study

Who may not be able to join:

You are under 18 years of age
You have been taking disease-modifying medications (DMARDs) for less than 1 year
You are not willing to take part in this type of observational study (called a cohort study)

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 7 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

Peking University Third Hospital

Registry

ClinicalTrials.gov

Start date

1 January 2023

Est. completion

31 December 2025

Where this trial is recruiting

🇨🇳 China

Primary endpoints

DAS28-ESR

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 7 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov